• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (4614794)   Today's Articles (0)   Subscriber (49390)
For: Onan D, Pipolo L, Yang E, Hannan RD, Thomas WG. Urotensin II Promotes Hypertrophy of Cardiac Myocytes via Mitogen-Activated Protein Kinases. Mol Endocrinol 2004;18:2344-54. [PMID: 15205471 DOI: 10.1210/me.2003-0309] [Citation(s) in RCA: 78] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]  Open
Number Cited by Other Article(s)
1
Nassour H, Pétrin D, Devost D, Billard E, Sleno R, Hébert TE, Chatenet D. Evidence for heterodimerization and functional interaction of the urotensin II and the angiotensin II type 1 receptors. Cell Signal 2024;116:111056. [PMID: 38262555 DOI: 10.1016/j.cellsig.2024.111056] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2024] [Accepted: 01/15/2024] [Indexed: 01/25/2024]
2
Palanisamy S, Xue C, Ishiyama S, Naga Prasad SV, Gabrielson K. GPCR-ErbB transactivation pathways and clinical implications. Cell Signal 2021;86:110092. [PMID: 34303814 DOI: 10.1016/j.cellsig.2021.110092] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/08/2021] [Revised: 07/18/2021] [Accepted: 07/19/2021] [Indexed: 11/18/2022]
3
Konno N, Takano M, Miura K, Miyazato M, Nakamachi T, Matsuda K, Kaiya H. Identification and signaling characterization of four urotensin II receptor subtypes in the western clawed frog, Xenopus tropicalis. Gen Comp Endocrinol 2020;299:113586. [PMID: 32828811 DOI: 10.1016/j.ygcen.2020.113586] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/30/2020] [Revised: 08/04/2020] [Accepted: 08/13/2020] [Indexed: 12/11/2022]
4
Tanner MA, Thomas TP, Grisanti LA. Death receptor 5 contributes to cardiomyocyte hypertrophy through epidermal growth factor receptor transactivation. J Mol Cell Cardiol 2019;136:1-14. [PMID: 31473246 DOI: 10.1016/j.yjmcc.2019.08.011] [Citation(s) in RCA: 16] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/19/2019] [Revised: 08/26/2019] [Accepted: 08/27/2019] [Indexed: 12/30/2022]
5
Pereira-Castro J, Brás-Silva C, Fontes-Sousa AP. Novel insights into the role of urotensin II in cardiovascular disease. Drug Discov Today 2019;24:2170-2180. [PMID: 31430542 DOI: 10.1016/j.drudis.2019.08.005] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/17/2019] [Revised: 07/26/2019] [Accepted: 08/12/2019] [Indexed: 12/16/2022]
6
Lim CJ, Kim NH, Park HJ, Lee BH, Oh KS, Yi KY. Synthesis and SAR of 5-aryl-furan-2-carboxamide derivatives as potent urotensin-II receptor antagonists. Bioorg Med Chem Lett 2019;29:577-580. [PMID: 30611618 DOI: 10.1016/j.bmcl.2018.12.058] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/21/2018] [Revised: 12/20/2018] [Accepted: 12/26/2018] [Indexed: 01/27/2023]
7
Wang BQ, Yang B, Yang HC, Wang JY, Hu S, Gao YS, Bu XY. MicroRNA-499a decelerates glioma cell proliferation while accelerating apoptosis through the suppression of Notch1 and the MAPK signaling pathway. Brain Res Bull 2018;142:96-106. [DOI: 10.1016/j.brainresbull.2018.06.005] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/22/2017] [Revised: 05/12/2018] [Accepted: 06/10/2018] [Indexed: 12/30/2022]
8
Cardiac GPCR-Mediated EGFR Transactivation: Impact and Therapeutic Implications. J Cardiovasc Pharmacol 2018;70:3-9. [PMID: 28059858 DOI: 10.1097/fjc.0000000000000462] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
9
Billard É, Iddir M, Nassour H, Lee-Gosselin L, Poujol de Molliens M, Chatenet D. New directions for urotensin II receptor ligands. Pept Sci (Hoboken) 2018. [DOI: 10.1002/pep2.24056] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
10
Xu J, Han Q, Shi H, Liu W, Chu T, Li H. Role of PKA in the process of neonatal cardiomyocyte hypertrophy induced by urotensin II. Int J Mol Med 2017;40:499-504. [PMID: 28656205 DOI: 10.3892/ijmm.2017.3038] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2016] [Accepted: 06/08/2017] [Indexed: 11/06/2022]  Open
11
Oh KS, Lee JH, Yi KY, Lim CJ, Park BK, Seo HW, Lee BH. A novel urotensin II receptor antagonist, KR-36996, improved cardiac function and attenuated cardiac hypertrophy in experimental heart failure. Eur J Pharmacol 2017;799:94-102. [PMID: 28163023 DOI: 10.1016/j.ejphar.2017.02.003] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2016] [Revised: 02/01/2017] [Accepted: 02/02/2017] [Indexed: 12/14/2022]
12
Castel H, Desrues L, Joubert JE, Tonon MC, Prézeau L, Chabbert M, Morin F, Gandolfo P. The G Protein-Coupled Receptor UT of the Neuropeptide Urotensin II Displays Structural and Functional Chemokine Features. Front Endocrinol (Lausanne) 2017;8:76. [PMID: 28487672 PMCID: PMC5403833 DOI: 10.3389/fendo.2017.00076] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/19/2016] [Accepted: 03/28/2017] [Indexed: 12/16/2022]  Open
13
Zhao J, Jiang J, Wang J, Liu L, Han XN, Chu SY, Xue L, Ding WH. Genetic polymorphisms ofUTS2rs2890565 Ser89Asn in cardiac hypertrophy in Chinese Han population. Postgrad Med J 2016;93:406-413. [DOI: 10.1136/postgradmedj-2016-134476] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2016] [Revised: 10/25/2016] [Accepted: 11/15/2016] [Indexed: 01/12/2023]
14
Benzo[ b ]thiophene-2-carboxamide derivatives as potent urotensin-II receptor antagonists. Bioorg Med Chem Lett 2016;26:4684-4686. [DOI: 10.1016/j.bmcl.2016.08.049] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/03/2016] [Revised: 08/12/2016] [Accepted: 08/18/2016] [Indexed: 02/07/2023]
15
Park CH, Lee JH, Lee MY, Lee JH, Lee BH, Oh KS. A novel role of G protein-coupled receptor kinase 5 in urotensin II-stimulated cellular hypertrophy in H9c2UT cells. Mol Cell Biochem 2016;422:151-160. [PMID: 27613164 DOI: 10.1007/s11010-016-2814-y] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2016] [Accepted: 08/29/2016] [Indexed: 12/26/2022]
16
Urotensin II induction of neonatal cardiomyocyte hypertrophy involves the CaMKII/PLN/SERCA 2a signaling pathway. Gene 2016;583:8-14. [DOI: 10.1016/j.gene.2016.02.039] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2015] [Revised: 02/08/2016] [Accepted: 02/24/2016] [Indexed: 12/16/2022]
17
Cashman TJ, Josowitz R, Johnson BV, Gelb BD, Costa KD. Human Engineered Cardiac Tissues Created Using Induced Pluripotent Stem Cells Reveal Functional Characteristics of BRAF-Mediated Hypertrophic Cardiomyopathy. PLoS One 2016;11:e0146697. [PMID: 26784941 PMCID: PMC4718533 DOI: 10.1371/journal.pone.0146697] [Citation(s) in RCA: 62] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/09/2015] [Accepted: 12/21/2015] [Indexed: 12/22/2022]  Open
18
Lim CJ, Jang JY, Kim SH, Lee BH, Oh KS, Yi KY. 1,3,4-Thiadiazol-2-amine Derivatives as Urotensin-II Receptor (UT) Antagonists. B KOREAN CHEM SOC 2015. [DOI: 10.1002/bkcs.10475] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
19
Vaudry H, Leprince J, Chatenet D, Fournier A, Lambert DG, Le Mével JC, Ohlstein EH, Schwertani A, Tostivint H, Vaudry D. International Union of Basic and Clinical Pharmacology. XCII. Urotensin II, urotensin II-related peptide, and their receptor: from structure to function. Pharmacol Rev 2015;67:214-58. [PMID: 25535277 DOI: 10.1124/pr.114.009480] [Citation(s) in RCA: 67] [Impact Index Per Article: 7.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]  Open
20
Oh KS, Lee JH, Yi KY, Lim CJ, Lee S, Park CH, Seo HW, Lee BH. The orally active urotensin receptor antagonist, KR36676, attenuates cellular and cardiac hypertrophy. Br J Pharmacol 2015;172:2618-33. [PMID: 25597918 DOI: 10.1111/bph.13082] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/04/2014] [Revised: 12/11/2014] [Accepted: 01/13/2015] [Indexed: 12/29/2022]  Open
21
Lim CJ, Oh SA, Lee BH, Oh KS, Yi KY. Synthesis and SAR of thieno[3,2- b ]pyridinyl urea derivatives as urotensin-II receptor antagonists. Bioorg Med Chem Lett 2014;24:5832-5835. [DOI: 10.1016/j.bmcl.2014.09.089] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/19/2014] [Revised: 09/25/2014] [Accepted: 09/30/2014] [Indexed: 02/07/2023]
22
Tsai YT, Lee CY, Hsu CC, Chang CY, Hsueh MK, Huang EYK, Tsai CS, Loh SH. Effects of urotensin II on intracellular pH regulation in cultured human internal mammary artery smooth muscle cells. Peptides 2014;56:173-82. [PMID: 24768794 DOI: 10.1016/j.peptides.2014.04.011] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/01/2014] [Revised: 04/15/2014] [Accepted: 04/15/2014] [Indexed: 12/18/2022]
23
Chiu CZ, Wang BW, Shyu KG. Angiotensin II and the JNK pathway mediate urotensin II expression in response to hypoxia in rat cardiomyocytes. J Endocrinol 2014;220:233-46. [PMID: 24481965 DOI: 10.1530/joe-13-0261] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
24
Enayat S, Ceyhan MŞ, Başaran AA, Gürsel M, Banerjee S. Anticarcinogenic effects of the ethanolic extract of Salix aegyptiaca in colon cancer cells: involvement of Akt/PKB and MAPK pathways. Nutr Cancer 2013;65:1045-58. [PMID: 24168160 DOI: 10.1080/01635581.2013.850966] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
25
Urotensin II and the kidney. Curr Opin Nephrol Hypertens 2013. [PMID: 23197158 DOI: 10.1097/mnh.0b013e32835b6d57] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
26
Varghayee N, Krezel MA, Rezmann L, Chow L, Frauman AG, Louis WJ, Louis SN. Function and expression of ATIP and its variants in cardiomyoblast cell line H9c2. J Renin Angiotensin Aldosterone Syst 2013;16:79-91. [PMID: 23559668 DOI: 10.1177/1470320313483845] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2012] [Accepted: 12/31/2012] [Indexed: 11/16/2022]  Open
27
Jani PP, Narayan H, Ng LL. The differential extraction and immunoluminometric assay of Urotensin II and Urotensin-related peptide in heart failure. Peptides 2013;40:72-6. [PMID: 23270674 DOI: 10.1016/j.peptides.2012.12.014] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/15/2012] [Revised: 12/17/2012] [Accepted: 12/17/2012] [Indexed: 02/16/2023]
28
Sala V, Gallo S, Leo C, Gatti S, Gelb BD, Crepaldi T. Signaling to cardiac hypertrophy: insights from human and mouse RASopathies. Mol Med 2012;18:938-47. [PMID: 22576369 DOI: 10.2119/molmed.2011.00512] [Citation(s) in RCA: 35] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/28/2011] [Accepted: 05/04/2012] [Indexed: 12/19/2022]  Open
29
Koulis C, de Haan JB, Allen TJ. Novel pathways and therapies in experimental diabetic atherosclerosis. Expert Rev Cardiovasc Ther 2012;10:323-35. [PMID: 22390805 DOI: 10.1586/erc.12.13] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
30
Gao S, Oh YB, Park BM, Park WH, Kim SH. Urotensin II protects ischemic reperfusion injury of hearts through ROS and antioxidant pathway. Peptides 2012;36:199-205. [PMID: 22609449 DOI: 10.1016/j.peptides.2012.05.004] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/11/2012] [Revised: 05/08/2012] [Accepted: 05/08/2012] [Indexed: 12/19/2022]
31
Chen YL, Loh SH, Chen JJ, Tsai CS. Urotensin II prevents cardiomyocyte apoptosis induced by doxorubicin via Akt and ERK. Eur J Pharmacol 2012;680:88-94. [DOI: 10.1016/j.ejphar.2012.01.034] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/20/2011] [Revised: 01/27/2012] [Accepted: 01/28/2012] [Indexed: 12/23/2022]
32
Gruson D, Ginion A, Lause P, Ketelslegers JM, Thissen JP, Bertrand L. Urotensin II and urocortin trigger the expression of myostatin, a negative regulator of cardiac growth, in cardiomyocytes. Peptides 2012;33:351-3. [PMID: 22244812 DOI: 10.1016/j.peptides.2011.12.017] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/05/2011] [Revised: 12/30/2011] [Accepted: 12/30/2011] [Indexed: 01/11/2023]
33
Shyu KG, Wang BW, Chen WJ, Kuan P, Lin CM. Angiotensin II mediates urotensin II expression by hypoxia in cultured cardiac fibroblast. Eur J Clin Invest 2012;42:17-26. [PMID: 21627650 DOI: 10.1111/j.1365-2362.2011.02549.x] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
34
Gruson D, Thys F, Verschuren F. Diagnosing destabilized heart failure in the emergency setting: current and future biomarker tests. Mol Diagn Ther 2011;15:327-40. [PMID: 22188636 DOI: 10.1007/bf03256468] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
35
Li Y, Zhang H, Liao W, Song Y, Ma X, Chen C, Lu Z, Li Z, Zhang Y. Transactivated EGFR mediates α1-AR-induced STAT3 activation and cardiac hypertrophy. Am J Physiol Heart Circ Physiol 2011;301:H1941-51. [DOI: 10.1152/ajpheart.00338.2011] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
36
Tsoukas P, Kane E, Giaid A. Potential Clinical Implications of the Urotensin II Receptor Antagonists. Front Pharmacol 2011;2:38. [PMID: 21811463 PMCID: PMC3143724 DOI: 10.3389/fphar.2011.00038] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2010] [Accepted: 07/05/2011] [Indexed: 12/20/2022]  Open
37
Urotensin-2 promotes collagen synthesis via ERK1/2-dependent and ERK1/2-independent TGF-β1 in neonatal cardiac fibroblasts. Cell Biol Int 2011;35:93-8. [PMID: 20946103 DOI: 10.1042/cbi20090104] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
38
EGFR trans-activation by urotensin II receptor is mediated by β-arrestin recruitment and confers cardioprotection in pressure overload-induced cardiac hypertrophy. Basic Res Cardiol 2011;106:577-89. [DOI: 10.1007/s00395-011-0163-2] [Citation(s) in RCA: 43] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/05/2010] [Revised: 02/09/2011] [Accepted: 02/10/2011] [Indexed: 12/20/2022]
39
Targeting non-malignant disorders with tyrosine kinase inhibitors. Nat Rev Drug Discov 2011;9:956-70. [PMID: 21119733 DOI: 10.1038/nrd3297] [Citation(s) in RCA: 106] [Impact Index Per Article: 8.2] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
40
Behm DJ, Aiyar NV, Olzinski AR, McAtee JJ, Hilfiker MA, Dodson JW, Dowdell SE, Wang GZ, Goodman KB, Sehon CA, Harpel MR, Willette RN, Neeb MJ, Leach CA, Douglas SA. GSK1562590, a slowly dissociating urotensin-II receptor antagonist, exhibits prolonged pharmacodynamic activity ex vivo. Br J Pharmacol 2010;161:207-28. [PMID: 20718751 DOI: 10.1111/j.1476-5381.2010.00889.x] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]  Open
41
Gao S, Oh YB, Shah A, Park WH, Chung MJ, Lee YH, Kim SH. Urotensin II receptor antagonist attenuates monocrotaline-induced cardiac hypertrophy in rats. Am J Physiol Heart Circ Physiol 2010;299:H1782-9. [DOI: 10.1152/ajpheart.00438.2010] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
42
Harris GS, Lust RM, Katwa LC, Wingard CJ. Urotensin II alters vascular reactivity in animals subjected to volume overload. Peptides 2010;31:2075-82. [PMID: 20723572 PMCID: PMC2953595 DOI: 10.1016/j.peptides.2010.07.023] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/06/2009] [Revised: 07/27/2010] [Accepted: 07/27/2010] [Indexed: 11/29/2022]
43
Iglewski M, Grant SR. Urotensin II-induced signaling involved in proliferation of vascular smooth muscle cells. Vasc Health Risk Manag 2010;6:723-34. [PMID: 20859543 PMCID: PMC2941785 DOI: 10.2147/vhrm.s11129] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/10/2010] [Indexed: 01/02/2023]  Open
44
Gruson D, Ginion A, Decroly N, Lause P, Vanoverschelde JL, Ketelslegers JM, Bertrand L, Thissen JP. Urotensin II induction of adult cardiomyocytes hypertrophy involves the Akt/GSK-3beta signaling pathway. Peptides 2010;31:1326-33. [PMID: 20416349 DOI: 10.1016/j.peptides.2010.04.009] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/03/2010] [Revised: 04/14/2010] [Accepted: 04/14/2010] [Indexed: 11/22/2022]
45
Guidolin D, Albertin G, Ribatti D. Urotensin-II as an angiogenic factor. Peptides 2010;31:1219-24. [PMID: 20346384 DOI: 10.1016/j.peptides.2010.03.022] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/18/2010] [Revised: 03/17/2010] [Accepted: 03/17/2010] [Indexed: 02/07/2023]
46
Guidolin D, Albertin G, Oselladore B, Sorato E, Rebuffat P, Mascarin A, Ribatti D. The pro-angiogenic activity of urotensin-II on human vascular endothelial cells involves ERK1/2 and PI3K signaling pathways. ACTA ACUST UNITED AC 2010;162:26-32. [PMID: 20171992 DOI: 10.1016/j.regpep.2010.02.009] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/12/2009] [Revised: 12/17/2009] [Accepted: 02/11/2010] [Indexed: 02/07/2023]
47
Aita Y, Kasahara T, Isobe K, Kawakami Y, Takekoshi K. Effect of urotensin II on PC12 rat pheochromocytoma cells. J Neuroendocrinol 2010;22:83-91. [PMID: 20025629 DOI: 10.1111/j.1365-2826.2009.01944.x] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
48
Urotensin II Activates Sarcolemmal Na+/H+ Exchanger in Adult Rat Ventricular Myocytes. J Cardiovasc Pharmacol 2010;55:191-7. [DOI: 10.1097/fjc.0b013e3181cf0074] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
49
Chen YH, Yandle TG, Richards AM, Palmer SC. Urotensin II immunoreactivity in the human circulation: evidence for widespread tissue release. Clin Chem 2009;55:2040-8. [PMID: 19797715 DOI: 10.1373/clinchem.2009.131748] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
50
Liu JC, Chen CH, Chen JJ, Cheng TH. Urotensin II Induces Rat Cardiomyocyte Hypertrophy via the Transient Oxidization of Src Homology 2-Containing Tyrosine Phosphatase and Transactivation of Epidermal Growth Factor Receptor. Mol Pharmacol 2009;76:1186-95. [DOI: 10.1124/mol.109.058297] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]  Open
PrevPage 1 of 2 12Next
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA